Capital International Investors
NTLA icon

Capital International Investors’s Intellia Therapeutics NTLA Stock Holding History

Capital International Investors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,779,424
Closed -$26.9M – 463
2025
Q1 		$26.9M Buy
+3,779,424
New +$38.2M 0.01% 373

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors's NTLA Position: Q2 2025 in Review

Capital International Investors sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 3,779,424 shares — an estimated $26.9M sold.

Capital International Investors first reported a position in NTLA in Q1 2025 and held it in 1 quarter. The position peaked at $26.9M in Q1 2025. 281 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Capital International Investors reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital International Investors sold 3,779,424 Intellia Therapeutics shares in Q2 2025, an estimated $26.9M.
  • Capital International Investors first reported a position in Intellia Therapeutics in Q1 2025 and held it in 1 quarter.
  • Capital International Investors's Intellia Therapeutics position peaked at $26.9M in Q1 2025.
  • 281 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Capital International Investors's 13F filing for Q2 2025, filed 13 Aug 2025.